1. Pink Sheet

Hahn's Priorities For US FDA Eschew Hot-Button Issues, Focus on Traditional Themes

 
• By Derrick Gingery

Promoting innovation, expansion of data use, and patient and consumer empowerment will affect agency work going forward, the FDA Commissioner said in his first all-staff address. Absent from his all-hands memo was drug pricing, opioids, or any other potentially political themes.  

Commissioner Stephen Hahn addresses FDA staff for the first time on 30 January 2020; his accompanying all-hands memo did not mention controversial issues like drug pricing or opioids. • Source: FDA

Commissioner Stephen Hahn sketched a vision for the US Food and Drug Administration focused on traditional themes, rather than ongoing crises and hot-button policy questions, during his first speech to staff.

In a memo to employees summarizing his remarks sent after the 30 January address, Hahn outlined three key topics that were important to

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from US FDA

More from Agency Leadership